Idiopathic myelofibrosis — an update with particular reference to clinical aspects and prognosis

  • Hans Carl Hasselbalch
Reviews

Summary

Idiopathic myelofibrosis (IMF) is characterized by excessive accumulation of connective tissue in the bone marrow as part of a clinical syndrome which in its classical form is featured by leukoerythroblastic anemia and huge splenomegaly at the time of diagnosis. An acute variant of the disease exists being featured by pancytopenia, nor or minimal splenomegaly and a rapidly fatal clinical course. This review describes the relationship of IMF to other chronic myeloproliferative disorders and highlights current concepts of the pathogenesis of bone marrow fibrosis, implicating the intramedullary release of various growth factors, including platelet-derived growth factor, epidermal growth factor and transforming growth factor beta. In a subgroup of patients bone marrow fibrosis may develop consequent to autoimmune bone marrow damage.

The clinical and laboratory findings in some of the larger series of patients are presented and the reasons for the highly variable clinical presentation and prognosis are critically discussed. It is proposed that studies on prognosis in IMF are based upon simple prognostic staging systems, which should include the Hb-concentration, platelet count, spleen size and the presence/absence of osteomyelosclerosis on X-ray. Using these parameters the patients are easily categorized into three prognostic groups with highly different survival times.

Key words

Idiopathic myelofibrosis Pathogenesis Clinical aspects Prognosis 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andreasen AP, Myelofibrosis. Munksgaard, Copenhagen, 1958.Google Scholar
  2. 2.
    Anger B, Seidler R, Haug U, Popp C, Heimpel H, Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica (Budap) 75: 228, 1990Google Scholar
  3. 3.
    Apaja-Sarkkinen M, Autio-Harmainen H, Alavaikko M, Risteli J, Risteli L, Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br J Haematol 63: 571, 1986PubMedGoogle Scholar
  4. 4.
    Arlet PH, Nicodeme R, Adoue D, Larregain-Fournier D, Delsol G, Le Tallec Y, Clinical evidence for 1.25 hydroxy-cholecalciferol action in myelofibrosis. Lancet I: 1013, 1984CrossRefGoogle Scholar
  5. 5.
    Arrago JP, Poirier O, Najean Y, Evolution des polyglobulies primitives vers la myelofibrosis. Surveillance par le dosage de l’aminopropetide du’ procollagen III. Presse Med 13: 2429, 1984PubMedGoogle Scholar
  6. 6.
    Arrago JP, Poirier O, Chomienne C, D’Agay MF, Najean Y, Type III aminoterminal propeptide of procollagen in some haematological malignancies. Scand J Haematol 36: 288, 1986PubMedCrossRefGoogle Scholar
  7. 7.
    Assmann H, Beiträge zur osteosclerotischen Anaemie. Beitr Pathol Anat 41: 565, 1907Google Scholar
  8. 8.
    Baglin TP, Simpson AW, Price SM, Boughton BJ, Composition of immune complexes and their relation to plasma fibronectin in chronic myeloprofilerative disorders. J Clin Pathol 49: 1468, 1987Google Scholar
  9. 9.
    Baglin TP, Price SM, Boughton BJ, A reversible defect of platelet PDGF content in myeloproliferative disorders. Br J Haematol 69: 483, 1988PubMedGoogle Scholar
  10. 10.
    Barge J, Slabodsky-Brousse N, Bernard JF, Histoimmunology of myelofibrosis: a study of 100 cases. Biomedicine 29: 73, 1978PubMedGoogle Scholar
  11. 11.
    Barnes HM, Prchal JT, Scott CW, Extramedullary blast transformation in the central nervous system in idiopathic myelofibrosis. Am J Hematol 11: 305, 1981PubMedCrossRefGoogle Scholar
  12. 12.
    Barosi G, Polino G, Chronic myelofibrosis with myeloid metaplasia. The spectrum of clinical syndromes. Haematologica (Pavia) 72: 553, 1987Google Scholar
  13. 13.
    Barosi G, Cazzola M, Frassoni F, Orlandi E, Stefanelli M, Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics. Br J Haematol 48: 262, 1981Google Scholar
  14. 14.
    Barosi G, Barzuini C, Liberato LN, Costa N, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70: 397, 1988PubMedGoogle Scholar
  15. 15.
    Barosi G, Costa A, Liberato N, Polino G, Spriano P, Magrini U, Serum procollagen-III-peptide level correlates with disease activity in myclofibrosis with myeloid metaplasia. Br J Haematol 72: 16, 1989PubMedGoogle Scholar
  16. 16.
    Bastrup-Madsen P, Myelosclerotic anemia. Acta Radiol 37: 189, 1952PubMedGoogle Scholar
  17. 17.
    Benbassat J, Penchas S, Ligumski M, Splenectomy in patients with agnogenic myeloid metaplasia. An analysis of 321 published cases. Br J Haematol 42: 207, 1979PubMedGoogle Scholar
  18. 18.
    Ben-Chetrit E, Gross DJ, Okon E, Levo Y, The association between autoimmunity and agnogenic myeloid metaplasia. Scand J Haematol 31: 410, 1983PubMedCrossRefGoogle Scholar
  19. 19.
    Bentley SA, Murray Lewis SM, Roberts PD, Erythroid hypoplasia in myelofibrosis: a feature associated with blastic transformation. Br J Haematol 36: 41, 1977PubMedGoogle Scholar
  20. 20.
    Bentley SA, Alabaster O, Foidart JM, Collagen heterogeneity in normal bone marrow. Br J Haematol 48: 287, 1981PubMedGoogle Scholar
  21. 21.
    Bernabei PA, Arcangeli A, Casini M, Grossi A, Padovani R, Ferrini PR, Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br J Haematol 63: 353, 1986PubMedCrossRefGoogle Scholar
  22. 22.
    Besa EC, Nowell PC, Geller NL, Gardner FH, Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 49: 308, 1982PubMedCrossRefGoogle Scholar
  23. 23.
    Blendis LM, Banks DC, Ramboer C, Williams R, spleen blood flow and splanchnic haemodynamics in blood dyscrasia and other splenomegalies. Clin Sci 38: 73, 1970PubMedGoogle Scholar
  24. 24.
    Bouroncle BA, Leukemic reticuloendotheliosis (Hairy cell leukemia) Blood 53: 412, 1979PubMedGoogle Scholar
  25. 25.
    Bouroncle BA, Doan CA, Myelofibrosis. Clinical, hematological and pathologic study of 110 patients. Am J Med Sci 2: 697, 1962Google Scholar
  26. 26.
    Burkhardt R, The bone marrow in systemic lupus erythematosus. Semin Hematol 2: 29, 1965Google Scholar
  27. 27.
    Burkhardt R, Bartl R, Beil E, Demmler K, Hoffman E, Kronseder A, Myelofibrosis-osteomyelosclerosis syndromereview of literature and histomorphology. Adv Biosci 9: 1974Google Scholar
  28. 28.
    Burkhardt R, Frisch B, Bartl B, Bone marrow biopsy in haematological disorders. J Clin Pathol 35: 257, 1982PubMedGoogle Scholar
  29. 29.
    Burkhardt R, Bartl R, Jager K, Frisch B, Kettner B, Mahl G, Sund M, Working classification of chronic myeloproliferative disorders based on histological, haematological and clinical findings. J Clin Pathol 39: 237, 1986PubMedGoogle Scholar
  30. 30.
    Burstein SA, Malpass TW, Yee E, Kadin M, Brigden M, Adamson JW, Harker LA, Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br J Haematol 57: 383, 1984PubMedGoogle Scholar
  31. 31.
    Buyssens N, Bourgeois NH, Chronic myelocytic leukemia versus idiopathic myelofibrosis. Cancer 40: 1548, 1977PubMedCrossRefGoogle Scholar
  32. 32.
    Caligaris Cappio F, Vigliani R, Novarino A, Camussi G, Campana D, Gavosto F, Idiopathic myelofibrosis: a possible role for immune complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol 49: 17, 1981Google Scholar
  33. 33.
    Canalis E, McCarthy T, Centrella M, Growth factors and the regulation of bone remodelling. J Clin Invest 81: 277, 1988PubMedGoogle Scholar
  34. 34.
    Castro-Malaspina H, Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Berk PD, Castro-Malaspina H, Wasserman LR (eds) Myelofibrosis and the biology of connective tissue. New York, p 427, 1984Google Scholar
  35. 35.
    Castro-Malaspina H, Moore MAS, Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes. Nouv Rev Fr Hematol 24: 221, 1982PubMedGoogle Scholar
  36. 36.
    Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MAS, Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 57: 781, 1981PubMedGoogle Scholar
  37. 37.
    Cehreli C, Ezdinli EZ, Li CY, Krmpotic E, Blastic phase of agnogenic myeloid metaplasia simulating malignant lymphoma. Cancer 38: 1297, 1976PubMedCrossRefGoogle Scholar
  38. 38.
    Cervantes F, Pereira A, Marti J, Feliu E, Rozman C, Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. Br J Haematol 70: 279, 1988PubMedGoogle Scholar
  39. 39.
    Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C, Acute transformation in nonleukaemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol (Basel) 85: 124, 1991Google Scholar
  40. 40.
    Charron D, Roberts L, Couty MC, Binet JL, Biochemical and histological analysis of bone marrow collagen in myelofibrosis. Br J Haematol 41: 151, 1979PubMedGoogle Scholar
  41. 41.
    Chelloul N, Briere J, Laval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C, Prognostic of myeloid metaplasia with myelofibrosis. Biomedicine 24: 272, 1976PubMedGoogle Scholar
  42. 42.
    Christensen BE, Erythrocyte pooling and sequestration in enlarged spleens. Estimations of splenic erythrocyte and plasma volume in splenomegalic patients. Scand J Haematol 10: 106, 1973PubMedCrossRefGoogle Scholar
  43. 43.
    Clough V, Geary CG, Hashmi K, Davson J, Knowlson T, Myelofibrosis in chronic granulocytic leukaemia. Br J Haematol 42: 515, 1979PubMedGoogle Scholar
  44. 44.
    Cornfiels DB, Hipkin P, Alavi A, Becker J, Peyster R, Intracranial myeloid metaplasia: diagnosis by CT and Fe52 scans and treatment by cranial irradiation. Am J Hematol 15: 273, 1983CrossRefGoogle Scholar
  45. 45.
    Craig JIO, Anthony RS, Parker AC, Circulating progenitor cells in myclofibrosis: the effect of recombinant alpha 2b interferon in vivo and in vitro. Br J Haematol 78: 155, 1991PubMedGoogle Scholar
  46. 46.
    Daly HM, Scott GL, Myelofibrosis as a cause of pancytopenia in systemic lupus erythematosus. J Clin Pathol 36: 1219, 1983PubMedGoogle Scholar
  47. 47.
    Dameshek W, Some speculations on the myeloproliferative syndrome. Blood 6: 372, 1951PubMedGoogle Scholar
  48. 48.
    Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report of 47 cases. Blood 72: 855, 1988PubMedGoogle Scholar
  49. 49.
    Den Ottolander GJ, Te Velde J, Brederoo P, et al. Megakaryoblastic leukemia (acute myelofibrosis): a report of three cases. Br J Haematol 42: 9, 1979Google Scholar
  50. 50.
    Di Bella D, Brown GL, Immunologic dysfunction in the myeloproliferative disorders. Cancer 42: 149, 1978CrossRefGoogle Scholar
  51. 51.
    Dokal I, Jones L, Deemamode M, Lewis SM, Goldman JM, Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 71: 158, 1989PubMedGoogle Scholar
  52. 52.
    Donald G, Forrest PL, Eastham JM, Reilly JT, Reduced platelet PDGF levels in idiopathic myelofibrosis. Br J Haematol 78: 1586, 1991Google Scholar
  53. 53.
    Donhauser JL, The human spleen as an haematoplastic organ, as exemplified in a case of splenomegaly with sclerosis of the bone marrow. J Exp Med 10: 559, 1908CrossRefPubMedGoogle Scholar
  54. 54.
    Drouet L, Praloran V, Cywiner-Golenzer C, Trhen C, Flandrin G, Caen J, Deficit congenital en alpha granules plaquet taires et fibrose reticulinique medullaire. Hypothese Physiopathogenique. Nouv Rev Fr Haematol 23: 95, 1981Google Scholar
  55. 55.
    Dvorak HF, Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650, 1986PubMedCrossRefGoogle Scholar
  56. 56.
    Dupriez B, Demory JL, Lai JL, Penaux P, Bauters F, Prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 73: 1367, 1989Google Scholar
  57. 57.
    Editorial, The Budd-Chiari syndrome. BMJ 1: 1302, 1979Google Scholar
  58. 58.
    Epstein RJ, Joshua DE, Kronenberg H, Idiopathic myelofibrosis complicated by lymphoma. Acta Haematol (Basel) 73: 40, 1985Google Scholar
  59. 59.
    Ester A, Feliu E, Aguilar JL, et al, Fagocitosis de complejos immunes. Interes diagnostica y patogenetico en la mielofibrosis idiopatica, Sangre (Barc) 26: 567, 1981Google Scholar
  60. 60.
    Eugster C, Re GP del, Bucher U, The role of 1.25 dihydroxyvitamin D3 (1.25 (OH)2D3) in the treatment of idiopathic myelofibrosis. Br J Haematol 65: 381, 1987PubMedGoogle Scholar
  61. 61.
    Frisch B, Bartl R, Histology of myelofibrosis and osteomylosclerosis. In: Lewis SM (ed) Myelofibrosis. Pathophysiology and clinical management. Dekker, New York, pp 15–49, 1985Google Scholar
  62. 62.
    Froom P, Aghai E, Kinarty A, Lahat N, Decreased natural killer (NK) activity in patients with myeloproliferative disorders. Cancer 64: 1038, 1989PubMedCrossRefGoogle Scholar
  63. 63.
    Gay S, Miller EJ, Collagen in the physiology and pathology of connective tissue. Fischer, Stuttgart 1978Google Scholar
  64. 64.
    Gay S, Gay RE, Prchal JT, Immunohistochemical studies of bone marrow collagen. In: Berk PD, Castro-Malaspina H, Wasserman LR (eds) Myelofibrosis and the biology of connective tissue. Liss, New York, pp 291–306, 1984Google Scholar
  65. 65.
    Georgii A, Vykoupil KF, Thiele J, Chronic megakaryocytic granulocytic myelosis—CMGM. A subtype of chronic myeloid leukemia. Virchows Arch [A] 389: 252, 1980Google Scholar
  66. 66.
    Georgii A, Vykoupil K, Thiele J, Classification of chronic myeloproliferative diseases by bone marrow biopsies. Hematological and cytogenetic findings and clinical course. Bibl Haematol 50: 41, 1984PubMedGoogle Scholar
  67. 67.
    Gersuk GM, Carmel R, Pattengale PK, Platelet-derived growth factor concentrations in platelet-poor-plasma and urine from patients with myeloproliferative disorders. Blood 74: 2330, 1989PubMedGoogle Scholar
  68. 68.
    Gilbert HS, The spectrum of myeloproliferative disorders. Med Clin Nor Am 57: 355, 1973Google Scholar
  69. 69.
    Gilbert HS, Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease. In: Berk PD, Castro-Malaspina H, Wasserman LR, (eds) Myelofibrosis and the biology of connective tissue. Liss, 3–17, New York, 1984Google Scholar
  70. 70.
    Glasser RM, Walker RI, Transition among the myeloproliferative disorders. Ann Intern Med 71: 285, 1968Google Scholar
  71. 71.
    Gordon B, Immunological abnormalities in myelofibrosis. In: Berk PD, Castro-Malaspina H, Wasserman LR (eds) Myelofibrosis and the biology of connective tissue, Liss, New York pp 455–463, 1984Google Scholar
  72. 72.
    Gordon BR, Coleman M, Kohen P, Day NK, Immunological abnormalities in myelofibrosis with activation of the complement system. Blood 5: 904, 1981Google Scholar
  73. 73.
    Gralnick HR, Harbor J, Vogel C, Myelofibrosis in chronic granulocytic leukaemia. Blood 37: 152, 1971PubMedGoogle Scholar
  74. 74.
    Groopman JE, The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 92: 857, 1980PubMedGoogle Scholar
  75. 75.
    Gustavsson P, Holm J, Wahlin A, Norberg B, Staging of idiopathic myelofibrosis. Significance of hemoglobin value and reticulocyte count. Acta Med Scand 218: 487, 1985PubMedCrossRefGoogle Scholar
  76. 76.
    Haedersdal C, Hasselbalch H, Devantier A, Saunamäki K, Pericardial haematopoiesis with tamponade in myelofibrosis. Scand J Haematol 34: 270, 1985PubMedCrossRefGoogle Scholar
  77. 77.
    Hansen NE, Killmann SA, Paroxysmal nocturnal hemoglobinuria in myelofibrosis. Blood 36: 161, 1970Google Scholar
  78. 78.
    Hasselbalch H, Urinary hydroxyproline excretion in the myelofibrosis-osteomyelosclerosis syndrome and related chronic myeloproliferative disorders. Eur J Haematol 39: 447, 1987PubMedCrossRefGoogle Scholar
  79. 79.
    Hasselbalch H, Interferon in myelofibrosis. Lancet I: 355, 1988CrossRefGoogle Scholar
  80. 80.
    Hasselbalch H, A possible role for interferon in the treatment of myelofibrosis. Med Hypotheses 27: 345, 1988PubMedCrossRefGoogle Scholar
  81. 81.
    Hasselbalch H, Idiopathic myelofibrosis. A clinical study of 80 patients. Am J Haematol 34: 291, 1990CrossRefGoogle Scholar
  82. 82.
    Hasselbalch H, Idiopathic myelofibrosis. A review. Eur J Haematol 45: 65, 1990PubMedCrossRefGoogle Scholar
  83. 83.
    Hasselbalch H, Berild D, Transition of myelofibrosis to polycythaemia vera. Scand J Haematol 30: 161, 1983PubMedCrossRefGoogle Scholar
  84. 84.
    Hasselbalch H, Clemmensen I, Plasma fibronectin in chronic myeloproliferative disorders. Scand J Clin Lab Invest 47: 429, 1987PubMedCrossRefGoogle Scholar
  85. 85.
    Hasselbalch J, Jensen BA, Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance. Eur J Haematol 44: 172, 1990PubMedCrossRefGoogle Scholar
  86. 86.
    Hasselbalch H, Lisse I, A sequential histological study of bone marrow collagen in idiopathic myelofibrosis. Eur J Haematol 46: 285, 1991PubMedCrossRefGoogle Scholar
  87. 87.
    Hasselbalch H, Berild D, Paaske-Hansen O, Red-cell sensitization in myelofibrosis. Scand J Haematol 32: 179, 1984PubMedCrossRefGoogle Scholar
  88. 88.
    Hasselbalch H, Berild D, Paaske-Hansen O, Platelet-associated IgG and IgM in myelofibrosis. Scand J Haematol 32: 488, 1984PubMedCrossRefGoogle Scholar
  89. 89.
    Hasselbalch H, Lisse I, Berild D, Videbaek A, Spongy lymphoid myelofibrosis as a predictor of hairy cell leukaemia or a variant of hairy cell leukaemia without hairy cells? Scand J Haematol 32: 1328, 1984Google Scholar
  90. 90.
    Hasselbalch H, Junker P, Lisse I, Bentsen KD, Serum procollagen III peptide in chronic myeloproliferative disorders. Scand J Haematol 35: 550, 1985PubMedCrossRefGoogle Scholar
  91. 91.
    Hasselbalch H, Nielsen H, Berild D, Kappelgaard KD, Circulating immune complexes in myelofibrosis. Scand J Haematol 34: 177, 1985PubMedCrossRefGoogle Scholar
  92. 92.
    Hasselbalch H, Junker P, Lisse I, Bentsen KD, Risteli L, Risteli J, Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders. Am J Hematol 23: 101, 1986PubMedCrossRefGoogle Scholar
  93. 93.
    Hasselbalch H, Jans H, Nielsen PL, A distinct subtype of idiopathic myelofibrosis with bone marrow features mimic king hairy cell leukaemia. Evidence for an autoimmune pathogenesis. Am J Hematol 25: 225, 1987PubMedCrossRefGoogle Scholar
  94. 94.
    Hasselbalch H, Junker P, Hørslev-Petersen K, Lisse I, Bentsen KD, Procollagen type III amino-terminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol 34: 291, 1990PubMedCrossRefGoogle Scholar
  95. 95.
    Heller EL, Lewisohn MG, Palin WE, Aleukemic myelosis, chronic nonleukemic myelosis, agnogenic myeloid metaplasia, osteosclerosis leukoerythroblastic anemia, and synonymous designations. Am J Pathol 23: 327, 1947PubMedGoogle Scholar
  96. 96.
    Hernandez Nieto L, Morey M, Granena A, Montserrat E, Feliu E, Rozman C, Les nodules lymphoides de la moelle dans la splenomegalie myeloide: comparison avec la leucemie myeloide chronique. Nouv Rev Fr Hematol 21: 251, 1979PubMedGoogle Scholar
  97. 97.
    Hertenstein B, Kurrle E, Frickhofen N, Heil G, Heimpel H, Aggressive polychemotherapy for acute myelofibrosis. Eur J Haematol 44: 213, 1990PubMedCrossRefGoogle Scholar
  98. 98.
    Heuck G, Zwei Fälle von Leukaemie mit eigentümlichen Blut resp. Knochenmarksbefund. Virchows Arch 78: 475, 1879Google Scholar
  99. 99.
    Hickling RA, Chronic non-leukaemic myelosis. QJ Med 6: 253, 1937Google Scholar
  100. 100.
    Hickling RA, The natural history of chronic non-leukemic myelosis. QJ Med 37: 267, 1968Google Scholar
  101. 101.
    Hitti-Harber J, Wohl H, Harper E, Platelet factor 4: an inhibitor of collagenase. Science 199: 991, 1978CrossRefGoogle Scholar
  102. 102.
    Hochweiss S, Fruchtman S, Hahn EG, Gilbert H, Donovan PB, Johnson J, Goldberg JD, Berg PD, Increased serum procollagen III aminoterminal peptide in myelofibrosis. Am J Hematol 15: 343, 1983PubMedCrossRefGoogle Scholar
  103. 103.
    Hunstein W, Experimental myelofibrosis. In: Videbaek A (ed) Polycythaemia vera and myelofibrosis. Clinics in Haematology, vol. II, Saunders London, pp 457–478, 1975Google Scholar
  104. 104.
    Iki S, Yagisawa M, Ohbayashi Y, Sato H, Urabe A, Adverse effect of erythropoietin in myeloproliferative disorders. Lancet 337: 187, 1991PubMedCrossRefGoogle Scholar
  105. 105.
    Ikkala E, Rapola J, Kontilaninen M, Polycythaemia vera and myelofibrosis. Scand J Haematol 4: 453, 1967PubMedCrossRefGoogle Scholar
  106. 106.
    Jacobson RJ, Salo A, Fialkow PJ, Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51: 189, 1978PubMedGoogle Scholar
  107. 107.
    Kaelin WG, Spivak JL, Systemic lupus erythematosus and myelofibrosis. Am J Med 81: 935, 1986PubMedCrossRefGoogle Scholar
  108. 108.
    Katoh O, Kimura A, Kuramoto A. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol 27:276, 1988.PubMedCrossRefGoogle Scholar
  109. 109.
    Keller JR, Sing GK, Ellingsworth LR, Rusceytti FW. Transforming growth factor beta: possible roles in the regulation of normal and leukemic haematopoietic cell growth. J Cell Biochem 39:175, 1989.PubMedCrossRefGoogle Scholar
  110. 110.
    Khumbanonda M, Horowitz HI, Eyster ME. Coombs’ positive hemolytic anemia in myelofibrosis with myeloid metaplasia. Am J Med Sci 258:89, 1969.PubMedCrossRefGoogle Scholar
  111. 111.
    Killmann S, Myelofibrosis. Clin Orthop 52:95, 1967PubMedGoogle Scholar
  112. 112.
    Kimura A, Katoh O, Kuramoto A, Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor β on the growth of human marrow fibroblasts. Br J Haematol 69:9, 1988PubMedGoogle Scholar
  113. 113.
    Kimura A, Katoh O, Kuramoto A, Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human mitogens. Br J Haematol 69:153, 1988PubMedGoogle Scholar
  114. 114.
    Kimura A, Katoh O, Hyodo H, Kuramoto A, Transforming growth factor-β regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 72:486, 1989.PubMedGoogle Scholar
  115. 115.
    Kreibe H, Jaquet K, Felgner J, Radzun HJ, Parwaresch MR, Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78:1814, 1991.Google Scholar
  116. 116.
    Kroener F, McMillan R, Beutler E, Acute myelofibrosis: treatment with allogeneic bone marrow transplantation. J Am Med Assoc 249:1189, 1983.CrossRefGoogle Scholar
  117. 117.
    Kuo CY, Van Voolen GA, Morrison AN, Primary and secondary myelofibrosis: its relationship to PNH-like defect. Blood 40:875, 1972.PubMedGoogle Scholar
  118. 118.
    Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 78:161, 1991.PubMedGoogle Scholar
  119. 119.
    Lang JM, Oberling F, Mayer S, Heid E, Autoimmunity in primary myelofibrosis. Biomedicine 25:39, 1976PubMedGoogle Scholar
  120. 120.
    Lau KS, White JC. Myelosclerosis associated with systemic lupus erythematous in patients in West Malaysia. J Clin Pathol 22:433, 1969.PubMedGoogle Scholar
  121. 121.
    Lau SO, Ramsey NKC, Smith CM, McKenna R, Kersey JH. Spontaneous resolution of severe childhood myclofibrosis. J Pediatr 98:585, 1981.PubMedCrossRefGoogle Scholar
  122. 122.
    Lazzarino M, Morra E, Castello A, Inverda D, Coci A, Pagnucco G, Magrini U, Zei G, Bernasconi C. Myelofibrosis in chronic granulocytic leukaemia. Clinicopathological correclations and prognostic significance. Br J Haematol 64:227, 1986PubMedGoogle Scholar
  123. 123.
    Lewis CM, Pegrum GD. Immune complexes in myelofibrosis: a possible guide to management. Br J Haematol 39:233, 1978PubMedGoogle Scholar
  124. 124.
    Lewis SM, Szur L. Malignant myelosclerosis. BMJ 2:472, 1963.PubMedGoogle Scholar
  125. 125.
    Lewis SM, Pettit JE, Tattersall MHN, Pepys MB. Myelosclerosis and paroxysmal nocturnal haemoglobinuria. Scand J Haematol 8:451, 1971PubMedCrossRefGoogle Scholar
  126. 126.
    Ligumski M, Polliack A, Benbassat J. Nature and incidence of liver involvement in agnogenic myeloid metaplasia. Scand J Haematol 21:81, 1978PubMedCrossRefGoogle Scholar
  127. 127.
    Linman JW, Bethell FH, Agnogenic myeloid metaplasia. Am J Med 22:197, 1957.CrossRefGoogle Scholar
  128. 128.
    Lisse I, Hasselbalch H, Junker P. Bone marrow stroma in idiopathic myelofibrosis and other haematological disorders. An immunohistochemical study. Acta Pathol Microbiol Immunol Scand 99:171, 1991Google Scholar
  129. 129.
    Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 44:33, 1990PubMedCrossRefGoogle Scholar
  130. 130.
    Lohman TP, Beckman EN. Progressive myelofibrosis in agnogenic myeloid metaplasia. Arch Pathol Lab Med 107:593, 1983Google Scholar
  131. 131.
    Long MW, Williams JL, Mann KG, Expression of human bone-related proteins in the hematopoietic microenvironment. J Clin Invest 86:1387, 1990PubMedGoogle Scholar
  132. 132.
    Longley S, Caldwell JR, Panush R. Paraneoplastic vasculitis. Unique syndrome of cutaneous angiitis, and arthritis associated with myeloproliferative disorders. Am J Med 80:1027, 1986PubMedCrossRefGoogle Scholar
  133. 133.
    Lopez-Guillermo A, Cervantes F, Bruguera M, Pereira A, Felio E, Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis. A study of 10 patients. Acta Haematol (Basel) 85:184, 1991.CrossRefGoogle Scholar
  134. 134.
    Malmaeus J, Akre T, Adami HO, Hagberg H, Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. Br J Surg 73:720, 1988CrossRefGoogle Scholar
  135. 135.
    Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 33:453, 1984PubMedCrossRefGoogle Scholar
  136. 136.
    Manoharan A, Smart RC, Pitney WR. Prognostic factors in myelofibrosis. Pathology 14:455, 1982PubMedGoogle Scholar
  137. 137.
    Manoharan A, Chen CF, Wilson LS, Griffiths KA, Robinson DE. Ultrasonic characterization of splenic tissue in myelofibrosis: further evidence for reversal of fibrosis with chemotherapy. Eur J Haematol 40:149, 1988PubMedCrossRefGoogle Scholar
  138. 138.
    Manoharan A, Hargrave M, Gordon S, Effect of chemotherapy on tear drop poikilocytosis and other peripheral blood findings in myelofibrosis. Pathology 20:7, 1988.PubMedGoogle Scholar
  139. 139.
    Marcus RE, Hibbin JA, Matutes E, Whittle N, Waterfield MD, Goldman JM. Megakaryoblastic transformation of myelofibrobrosis with expression of the c-sis oncogene. Scand J Haematol 36:186, 1986PubMedCrossRefGoogle Scholar
  140. 140.
    Marquetty C, Labro-Bryskier M, Perlamin A, Hakin J. Impaired metabolic activity of phagocytosing neutrophils in agnogenic osteomyelosclerosis with splenomegaly. A longitudinal study. Am J Hematol 16:243, 1984PubMedCrossRefGoogle Scholar
  141. 141.
    Martyre M, Magdelenat H, Bryckaert M, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor-β in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 77:80, 1991PubMedGoogle Scholar
  142. 142.
    Martyre MC, Magdelenat H, Calvo F. Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 77:431, 1991PubMedGoogle Scholar
  143. 143.
    McCarthy DM, Hibbin JA, Goldman JM. A role for 1.25-dihydroxy vitamin D3 in control of bone marrow collagen deposition. Lancet 1:78, 1988Google Scholar
  144. 144.
    McCarthy D. Fibrosis of the bone marrow: content and causes. Br J Haematol 59:1, 1985PubMedGoogle Scholar
  145. 145.
    McCarthy D, Clark J, Giles F. The treatment of myelofibrosis with alfa-interferon. Br J Haematol 78:590, 1991PubMedGoogle Scholar
  146. 146.
    McKinley R, Kwan YL, Ford D, Lam-Po-Yong PR, Mason RS, Manoharan A. Clinical and laboratory studies of 1.25 dihydroxycholecalciferol in myelofibrosis. Br J Haematol 65:245, 1987Google Scholar
  147. 147.
    Meadows LM, Rosse WR, Moore JO, Crawford J, Laszlo J, Kaufman E. Hodgkin’s disease presenting as myelofibrosis. Cancer 1720, 1989Google Scholar
  148. 148.
    Mehta AB, Baughan, ASJ, Catovsky D, Goldman JM, Johnson SA, Galton DAG. Reversal of bone marrow fibrosis in acute megakaryocytic leukaemia after remission-induction and bone marrow transplantation. Br J Haematol 53:445, 1983PubMedGoogle Scholar
  149. 149.
    Meytes D, Katz D, Ramot B. Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythaemic. Isr Med J 12:534, 1976Google Scholar
  150. 150.
    Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythaemic myelofibrosis. Cancer 55:582, 1985PubMedCrossRefGoogle Scholar
  151. 151.
    Najean Y, Cacchione R, Castro-Malaspina H, Dresch C. Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol 40:205, 1978PubMedGoogle Scholar
  152. 152.
    Najean Y, Arago JP, Rain JD, Dresch C, The “spent” phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis. Br J Haematol 56:163, 1984PubMedGoogle Scholar
  153. 153.
    Nakai GS, et al. Agnogenic myeloid metaplasia. A survey of 29 cases and a review of the literature. Ann Intern Med 57:419, 1962PubMedGoogle Scholar
  154. 154.
    Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC, Anaemia in myelofibrosis: its value in prognosis. Br J Haematol 54:79, 1983PubMedGoogle Scholar
  155. 155.
    Ogawa M, Annotation: cellular mechanisms of myeloproliferative disorders. Br J Haematol 58:563, 1984PubMedGoogle Scholar
  156. 156.
    Özsoylu S, Ruacan S, High-dose intravenous corticosteroid treatment in childhood idiopathic myelofibrosis. Acta Haematol (Basel) 75:49, 1982Google Scholar
  157. 157.
    Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ, Mufti GJ, Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of ten cases. Br J Haematol 71:499, 1989PubMedGoogle Scholar
  158. 158.
    Parmeggiani L, Ferrant A, Rodhain J, Michaux JL, Sokal G, Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39:228, 1987PubMedCrossRefGoogle Scholar
  159. 159.
    Pegrum GD, Risdon RA, The haematological and histological findings in 18 patients with clinical features resembling those of myelofibrosis. Br J Haematol 18:475, 1970PubMedGoogle Scholar
  160. 160.
    Pereira A, Bruguera F, Cervantes F, Rozman C, Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol 40:355, 1988PubMedCrossRefGoogle Scholar
  161. 161.
    Pereira A, Cervantes F, Brugues R, Rozman C, Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol 44:94, 1990Google Scholar
  162. 162.
    Petrini M, Cecconi N, Azzara A, Ambrogi F, Grassi B, 1.25-dihydroxy-vitamin D3 in the treatment of idiopathic myelofibrosis. Br. J Haematol 624, 1986Google Scholar
  163. 163.
    Pettit JE, Lewis SM, Nicholas AW, Transitional, myeloproliferative disorder. Br J Haematol 43:167, 1979PubMedGoogle Scholar
  164. 164.
    Pfueller SL, Weber S, Luscher EF, Studies of the mechanism of the human platelet release reaction induced by immunological stimuli. III. Relationship between the binding of soluble IgG aggregates to the Fc receptor and cell response in the presence and absence of plasma. J Immunol 118:514, 1977PubMedGoogle Scholar
  165. 165.
    Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS, A clinical study of seventy cases of myelofibrosis. Ann Intern Med 57:73, 1962PubMedGoogle Scholar
  166. 166.
    Polliack A, Prokocimer M, Matzner Y, Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 9:211, 1980PubMedCrossRefGoogle Scholar
  167. 167.
    Ragni MV, Schreiner DP, Spontaneous “remission” of agnogenic myeloid metaplasia and termination in acute myeloid leukaemia. Arch Intern Med 141:1481, 1981PubMedCrossRefGoogle Scholar
  168. 168.
    Reilly JT, Nash JRG, Mackie MJ, McVerry BA, Immuno-enzymatic detection of fibronectin in normal and pathological haematopoietic tissue. Br J Haematol 59:497, 1985PubMedGoogle Scholar
  169. 169.
    Richard C, Mazzora F, Irionda A, Mazo E, Bello C, Zubizaretta A, The usefulness of 1.25-dihydroxy-vitamin D3 in the treatment of idiopathic myelofibrosis. Br J Haematol 62:399, 1986PubMedGoogle Scholar
  170. 170.
    Rojer RA, Mulder NH, Nieweg H, Response to pyridoxine hydrochloride in refractory anemia in myelofibrosis. Am J Med 65:655, 1978PubMedCrossRefGoogle Scholar
  171. 171.
    Romano M, Poggi A, Donati MB, Cortelazzo S, Viero P, Barbui T, Reduced platelet mitogenic activity in myeloproliferative disorders. Lancet II:345, 1986CrossRefGoogle Scholar
  172. 172.
    Rondeau E, Solal-Celigny P, Dhermy D, Vroclans M, Brousset N, Bernard JF, Boivin P, Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol 53:467, 1983PubMedGoogle Scholar
  173. 173.
    Rosenthal DS, Moloney WC, Myeloid metaplasia: a study of 98 cases. Postgrad Med 45:136, 1969PubMedGoogle Scholar
  174. 174.
    Rosenthal DS, Moloney WC, Occurrence of acute leukaemia in myeloproliferative disorders. Br J Haematol 36:373, 1977PubMedGoogle Scholar
  175. 175.
    Samuelsson SM, Killander A, Werner I, Stenkvist B, Myelofibrosis associated with tuberculous lymphadenitis. Acta Med Scand [Suppl] 179:326, 1966Google Scholar
  176. 176.
    Say B, Berkel AI Idiopathic myelofibrosis in infants. J Pediatr 580, 1964Google Scholar
  177. 177.
    Schafer AJ, Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1, 1984PubMedGoogle Scholar
  178. 178.
    Seewann HL, Gastl G, Lang A, Abbrederis K, Thaler J, Flener R, Huber CH, Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56:161, 1988PubMedCrossRefGoogle Scholar
  179. 179.
    Sclroos O, Skrifvars B, Wasastjerna C, Immunological deficiency in myelofibrosis. Scand J Haematol 11:307, 1973CrossRefGoogle Scholar
  180. 180.
    Shalev Goldfarb A, Ariel I, Rachmilewitz, Myelofibrosis in young adults. Acta Haematol (Basel) 70:396, 1983Google Scholar
  181. 181.
    Silvergleid AJ, Schrier SL, Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseases. Am J Med 57:885, 1974PubMedCrossRefGoogle Scholar
  182. 182.
    Silverstein MN, Agnogenic myeloid metaplasia. Publishing Science Group, Boston, 1975Google Scholar
  183. 183.
    Silverstein MN, Linman JW, Causes of death in agnogenic myeloid metaplasia. Mayo Clin Proc 44:36, 1969PubMedGoogle Scholar
  184. 184.
    Silverstein MN, ReMine WH, Splenectomy in myeloid metaplasia. Blood 53:515, 1979PubMedGoogle Scholar
  185. 185.
    Silverstein MN, Gomes MR, ReMine WH, Elveback LR, Agnogenic myeloid metaplasia: natural history and treatment. Arch Intern Med 120:545, 1967CrossRefGoogle Scholar
  186. 186.
    Silverstein MN, Wollager EE, Baggenstors AH, Gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Arch Intern Med 131:532, 1973PubMedCrossRefGoogle Scholar
  187. 187.
    Silverstein MN, Brown AL, Linman JW, Idiopathic myeloid metaplasia. Its evolution into acute leukaemia. Arch Intern Med 132:709, 1973PubMedCrossRefGoogle Scholar
  188. 188.
    Smith JW, Shulman HM, Thomas ED, Fefer A, Buckner CD, Bone marrow transplantation for acute myelofibrosis. Cancer 48:2198, 1981PubMedCrossRefGoogle Scholar
  189. 189.
    Smith RE, Chelmowski MK, Szabo EJ, Myelofibrosis: a concise review of clinical and pathologic features and treatment. Am J Hematol 29:174, 1988PubMedCrossRefGoogle Scholar
  190. 190.
    Söderstrom N, Bandmann U, Lundh B, Pathoanatomical features of the spleen and liver. Clin Haematol 4:309, 1975PubMedGoogle Scholar
  191. 191.
    Szur L, Smith MD, Red cell destruction and destruction in myelosclerosis. Br J Haematol 7:147, 1961PubMedGoogle Scholar
  192. 192.
    Szur L, Lewis SM, Iron kinetics (in polycythaemia vera and myelofibrosis). Clin Haematol 4:407, 1975PubMedGoogle Scholar
  193. 193.
    Sultan C, Sigaux F, Imbert M, Reyes F, Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 49:11, 1981PubMedGoogle Scholar
  194. 194.
    Sunami S, Fuse A, Simizu B, Eguchi M, Hayashi Y, Sugita K, Nakazawa S, Okimoto Y, Sato T, Nakajima H, The c-sis gene expression in cells from a patient with acute megakaryoblastic leukemia and Down’s syndrome. Blood 70:368, 1987PubMedGoogle Scholar
  195. 195.
    Takaczi-Nagy L, Graf F, Definition, clinical features and diagnosis of myelofibrosis. Clin Haematol 4:373, 1975Google Scholar
  196. 196.
    Terui T, Niitsu Y, Mahara K, Fujisaki Y, Urushizaki Y, Mogi Y, Kohgo Y, Watanabe N, Ogura M, Saito H, The production of transforming growth factor-β in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75:1540, 1990PubMedGoogle Scholar
  197. 197.
    Thiele J, Krech R, Vykoupil KF, Georgii A, Malignant (acute) myelosclerosis—a clinical and pathological study in 6 patients. Scand J Haematol 33:95, 1984PubMedCrossRefGoogle Scholar
  198. 198.
    Thiele J, Simon KG, Fischer R, Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteomyelofibrosis. Pathol Res Pract 183:434, 1988PubMedGoogle Scholar
  199. 199.
    Thiele J, Steinberg T, Zankovich R, Fischer R, Primary myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia): correlation of clinical findings with bone marrow histopathology and prognosis. Anticancer Res 9:429, 1989PubMedGoogle Scholar
  200. 200.
    Thiele J, Hoeppner B, Zankovich R, Fischer R, Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis sclerosis (agnogenic myeloid metaplasia)—correlations between clinical and morphological features. Virchows Arch [A] 415:191, 1989CrossRefGoogle Scholar
  201. 201.
    Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Dichl V, Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis—a critical evaluation of clinical and histomorphological data. Acta Haematol (Basel) 81:192, 1989Google Scholar
  202. 202.
    Thiele J, Kvasnicka HM, Steinberg T, Zankovich R, Fischer Dichl V, Survival in primary (idiopathic) osteomyelofibrosis, so-called agnogenic myeloid metaplasia. Leuk Lymph 6:389, 1992Google Scholar
  203. 203.
    Thiele J, Rompcik V, Wagner S, Fischer R, Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol 80:227, 1992PubMedGoogle Scholar
  204. 204.
    Truong LD, Saleem A, Schwartz R, Acute myelofibrosis. A report of four cases and review of the literature. Medicine (Baltimore) 63:182, 1984Google Scholar
  205. 205.
    Tsatalas C, Curtoglou G, Fotopoulos D, Halkia P, Vyzantiadis AT, Sinakos Z, I-Alfa (OH)D3 treatment and procollagen III (PCIII) studies in idiopathic myelofibrosis. Haematologica (Pavia) 74:559, 1989Google Scholar
  206. 206.
    Van Slyck EJ, Weiss L, Dully M, Chromosomal evidence for the secondary role of the fibroblast proliferation in acute myelofirbrosis. Blood 36:729, 1970PubMedGoogle Scholar
  207. 207.
    Varki A, Lottenborg R, Griffith R, Reinhard E, The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 62:353, 1983Google Scholar
  208. 208.
    Vellenga E, Mulder NH, Nieweg HO, A study of the cellular and humoral immune response in patients with myelofibrosis. Clin Lab Haematol 4:239, 1982PubMedCrossRefGoogle Scholar
  209. 209.
    Vellenga E, Mulder NH, Zanten HK van, Nieweg HO, Woldring MG, The significance of the aminoterminal propeptide of type III procollagen in paroxysmal nocturnal haemoglobinuria and myelofibrosis. Eur J Nucl Med 8:499, 1983PubMedCrossRefGoogle Scholar
  210. 210.
    Videbaek A, Christensen BE, Jønsson V, The spleen in health and disease. Chicago, London: Year Book Medical Publishers 1982Google Scholar
  211. 211.
    Visani G, Finelli C, Castelli U, Petti M, Ricci P, Vianelli N, Gianni L, Zuffa E, Alve Spiriti MA, Latagliata R, Pileri S, Magrini U, Gugliotta L, Morra E, Mernasconi C, Mandelli F, Tura S, Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4, 1990PubMedGoogle Scholar
  212. 212.
    Von Knorring J, Selroos OW, Wegelius O, Myeloid metaplasia in disseminated vascular disease. Acta Med Scand 195:137, 1974CrossRefGoogle Scholar
  213. 213.
    Wagner H, McKeough PG, Desforges J, Madoc-Jones H, Splenic irradiation in the treatment of patients with chronic myelogenous leukaemia or myelofibrosis with myeloid metaplasia. Cancer 58:1204, 1986PubMedCrossRefGoogle Scholar
  214. 214.
    Wang JC, Aung MK, Tobin MS, Urinary hydroxyproline excretion in myelofibrosis. Blood 55:383, 1980PubMedGoogle Scholar
  215. 215.
    Wang JC, Wong CK, Kao WW, Immunoreactive prolyl hydroxylase in patients with primary and secondary myelofibrosis. Br J Haematol 65:171, 1981Google Scholar
  216. 216.
    Wanless IR, Petersen P, Das A, Boitnott JK, Moore GW, Bernier V, Hepatic vascular disease and portal hypertension in polycythaemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 12:1166, 1990PubMedCrossRefGoogle Scholar
  217. 217.
    Ward HP, Block MH, The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 50:357, 1971Google Scholar
  218. 218.
    Weinstein IM, Idiopathic myelofibrosis: historical review, diagnosis and management. Blood Rev 5:98, 1991PubMedCrossRefGoogle Scholar
  219. 219.
    Whitehead S, Geary CG, Low dose cytosine arabinoside used to induced remission in acute myelofibrosis. Br J Haematol 58:375, 1984PubMedGoogle Scholar
  220. 220.
    Wolf BC, Neiman RS, Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 4:803, 1985Google Scholar
  221. 221.
    Wolf JL, Spruce WE, Bearman RM et al. Reversal of acute (“malignant”) myelosclerosis by allogenic bone marrow transplantation. Blood 59:191, 1982PubMedGoogle Scholar
  222. 222.
    Yonekura S, Nagao T, Arimori S, Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia. Br J Haematol 61:93, 1985PubMedGoogle Scholar
  223. 223.
    Yetgin S, Ozsoylu S. Myeloid metaplasia in vitamin D3 deficiency rickets. Scand J Haematol 180, 1982Google Scholar
  224. 224.
    Zankovich R, Thiele J, Modder B, Steinberg T, Simon KG, Fischer R, Dichl V, Die sogenannte primäre (idiopatische) Osteomyelofibrose/-sclerose (OMF) im Rahmen chronischer myeloproliferative Erkrankungen. I. Initiale klinische und histopathologische Befunde bei 102 Patienten mit besonders fortgeschrittenen fibrosclerotischen Stadien. Med Klin 19:617, 1988Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Hans Carl Hasselbalch
    • 1
  1. 1.Department of MedicineNæstved HospitalNæstvedDenmark

Personalised recommendations